This innovation is being developed to ensure the Medicines and Healthcare products Regulatory Agency (MHRA) guidance on the use of sodium valproate in girls and women of child-bearing age is implemented across the Kent and Medway system.
It builds on experience from an initiative in the then Medway and Swale Clinical Commissioning Group (CCG) in which an Epilepsy Specialist Pharmacist (ESP) reviewed patients working alongside the consultant neurologist.
Now in its second year, this pilot project is being adapted into a system-wide approach across Kent and Medway to enable robust and sustainable delivery of this important safety initiative.
